Intrahepatic portosystemic shunt in treatment of complications of portal XXXX .

@entity1 @entity101 @entity548 @entity843 @entity5273 @entity1575
BACKGROUND: The aim of the paper is to present the role of @entity5273 ( @entity5273 ) in the treatment of portal @entity101 complications such as @entity548 and persistent @entity843 . MATERIAL AND METHODS: Between June 1992 and December 2000, 56 @entity1 with portal @entity101 developed in the course of @entity1575 were qualified for @entity5273 . The indications for @entity5273 included esophageal @entity548 , recurrent despite endoscopic treatment (N-40), active esophageal @entity548 in which traditional methods used to stop the @entity548 proved ineffective (N-8) and @entity843 failing to respond to high doses of diuretic agents (N-8). The studied group consisted of 30 females and 26 male @entity1 aged from 17 to 68 (mean age 52 yrs). According to @entity1 -Pugh surgical risk classification, 26 @entity1 belonged to group B, and 30 to group C. RESULTS: In 50 @entity1 (83.5%) an intrahepatic shunt was formed and the stent(s) implanted. In 42 cases (75%), long-lasting patency of the shunt was obtained and esophageal @entity548 was stopped. Active esophageal @entity548 were stopped in all the cases. The remission of @entity843 was obtained in 7 out of 8 @entity1 . CONCLUSIONS: @entity5273 is a non-surgical method relieving portal @entity101 in @entity1 with @entity548 recurrent despite endoscopic treatment. Very good results were also obtained in the cases with active @entity548 . @entity5273 has proved to be an effective method of treatment in the @entity1 with @entity843 .
